199 related articles for article (PubMed ID: 17598983)
41. Do Mutations Turn p53 into an Oncogene?
Pitolli C; Wang Y; Mancini M; Shi Y; Melino G; Amelio I
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835684
[TBL] [Abstract][Full Text] [Related]
42. Targeting mutant p53 in cancer: a long road to precision therapy.
Mantovani F; Walerych D; Sal GD
FEBS J; 2017 Mar; 284(6):837-850. PubMed ID: 27808469
[TBL] [Abstract][Full Text] [Related]
43. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.
Cadwell C; Zambetti GP
Gene; 2001 Oct; 277(1-2):15-30. PubMed ID: 11602342
[TBL] [Abstract][Full Text] [Related]
44. Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.
Frum RA; Love IM; Damle PK; Mukhopadhyay ND; Palit Deb S; Deb S; Grossman SR
Mol Cancer Res; 2016 May; 14(5):423-36. PubMed ID: 26965143
[TBL] [Abstract][Full Text] [Related]
45. Cancer-specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis.
Candeias MM; Hagiwara M; Matsuda M
EMBO Rep; 2016 Nov; 17(11):1542-1551. PubMed ID: 27702985
[TBL] [Abstract][Full Text] [Related]
46. Mutant p53 gain of function induces HER2 over-expression in cancer cells.
Román-Rosales AA; García-Villa E; Herrera LA; Gariglio P; Díaz-Chávez J
BMC Cancer; 2018 Jul; 18(1):709. PubMed ID: 29970031
[TBL] [Abstract][Full Text] [Related]
47. Mutant p53 in Cancer Progression and Targeted Therapies.
Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
Front Oncol; 2020; 10():595187. PubMed ID: 33240819
[No Abstract] [Full Text] [Related]
48. Crippling p53 activities via knock-in mutations in mouse models.
Iwakuma T; Lozano G
Oncogene; 2007 Apr; 26(15):2177-84. PubMed ID: 17401426
[TBL] [Abstract][Full Text] [Related]
49. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.
Solomon H; Dinowitz N; Pateras IS; Cooks T; Shetzer Y; Molchadsky A; Charni M; Rabani S; Koifman G; Tarcic O; Porat Z; Kogan-Sakin I; Goldfinger N; Oren M; Harris CC; Gorgoulis VG; Rotter V
Oncogene; 2018 Mar; 37(12):1669-1684. PubMed ID: 29343849
[TBL] [Abstract][Full Text] [Related]
50. When mutants gain new powers: news from the mutant p53 field.
Brosh R; Rotter V
Nat Rev Cancer; 2009 Oct; 9(10):701-13. PubMed ID: 19693097
[TBL] [Abstract][Full Text] [Related]
51. Studies of ATM Kinase Activity Using Engineered ATM Sensitive to ATP Analogues (ATM-AS).
Enari M; Matsushima-Hibiya Y; Miyazaki M; Otomo R
Methods Mol Biol; 2017; 1599():145-156. PubMed ID: 28477117
[TBL] [Abstract][Full Text] [Related]
52. The role of p53-target genes in human cancer.
Tokino T; Nakamura Y
Crit Rev Oncol Hematol; 2000 Jan; 33(1):1-6. PubMed ID: 10714958
[TBL] [Abstract][Full Text] [Related]
53. Contribution of p53 to metastasis.
Powell E; Piwnica-Worms D; Piwnica-Worms H
Cancer Discov; 2014 Apr; 4(4):405-14. PubMed ID: 24658082
[TBL] [Abstract][Full Text] [Related]
54. Transcriptional regulation by mutant p53 and oncogenesis.
Santoro R; Strano S; Blandino G
Subcell Biochem; 2014; 85():91-103. PubMed ID: 25201190
[TBL] [Abstract][Full Text] [Related]
55. Disrupting TP53 in mouse models of human cancers.
Parant JM; Lozano G
Hum Mutat; 2003 Mar; 21(3):321-6. PubMed ID: 12619119
[TBL] [Abstract][Full Text] [Related]
56. Disarming mutant p53 oncogenic function.
Girardini JE; Marotta C; Del Sal G
Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
[TBL] [Abstract][Full Text] [Related]
57. Molecularly targeted therapies for p53-mutant cancers.
Zhao D; Tahaney WM; Mazumdar A; Savage MI; Brown PH
Cell Mol Life Sci; 2017 Nov; 74(22):4171-4187. PubMed ID: 28643165
[TBL] [Abstract][Full Text] [Related]
58. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
59. Mutant p53: an oncogenic transcription factor.
Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
[TBL] [Abstract][Full Text] [Related]
60. Mutant p53 in colon cancer.
Nakayama M; Oshima M
J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
